An experimental antibody therapy called ublituximab has been found to reduce symptom flare-ups in multiple sclerosis (MS) patients by preventing relapses and areas of inflammatory damage in the brain. If approved by the FDA, it would be the latest in a group of MS therapies called anti-CD20 monoclonal antibodies. Recent developments in this field show that high-efficacy medications, such as anti-CD20 antibodies, may benefit MS patients more than older drugs. However, the cost of these medications often depends on a patient’s insurance, with some anti-CD20 monoclonal antibodies currently priced at about $68,000 per year.
Source link
New MS Treatment Shows Promise in Trial
